Autolus Therapeutics plc (NASDAQ:AUTL) Receives Average Rating of “Buy” from Analysts

Autolus Therapeutics plc (NASDAQ:AUTL) has received a consensus rating of “Buy” from the six ratings firms that are presently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have covered the stock in the last year is $9.52.

Several brokerages have recently weighed in on AUTL. Needham & Company LLC reiterated a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, January 13th. Wells Fargo & Company decreased their price objective on Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating on the stock in a report on Friday, March 21st.

Autolus Therapeutics Trading Up 1.2 %

Shares of AUTL stock opened at $1.65 on Friday. Autolus Therapeutics has a 12 month low of $1.56 and a 12 month high of $6.44. The company has a market capitalization of $439.06 million, a P/E ratio of -1.36 and a beta of 2.07. The stock has a 50 day moving average of $1.97 and a two-hundred day moving average of $2.85.

Autolus Therapeutics (NASDAQ:AUTL) last issued its earnings results on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.12. The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $2.98 million. Sell-side analysts predict that Autolus Therapeutics will post -0.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Large investors have recently bought and sold shares of the business. Wellington Management Group LLP raised its position in Autolus Therapeutics by 4.6% in the 4th quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company’s stock valued at $59,562,000 after purchasing an additional 1,125,454 shares during the last quarter. TFG Asset Management GP Ltd raised its holdings in shares of Autolus Therapeutics by 3.1% in the fourth quarter. TFG Asset Management GP Ltd now owns 8,250,000 shares of the company’s stock valued at $19,388,000 after buying an additional 250,000 shares during the last quarter. Two Sigma Advisers LP raised its holdings in shares of Autolus Therapeutics by 4.8% in the fourth quarter. Two Sigma Advisers LP now owns 333,400 shares of the company’s stock valued at $783,000 after buying an additional 15,400 shares during the last quarter. Two Sigma Investments LP lifted its position in Autolus Therapeutics by 23.8% during the 4th quarter. Two Sigma Investments LP now owns 906,767 shares of the company’s stock worth $2,131,000 after buying an additional 174,485 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in Autolus Therapeutics during the 4th quarter worth about $581,000. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.